Midazolam prevents motor neuronal death from oxidative stress attack mediated by JNK-ERK pathway

Guo-Zheng Li1, Hong-Lei Tao1, Cheng Zhou1

  • 1Department of Anesthesiology, Tongde Hospital of Zhejiang Province, 234 Gucui Road, Hangzhou, 310012, Zhejiang, China.

Human Cell
|October 13, 2017
PubMed

Insights

Midazolam protects motor neurons from oxidative stress by reducing apoptosis. This sedative may be a promising treatment for motor neuron diseases by modulating the JNK-ERK signaling pathway.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cell Biology

Background:

  • Midazolam is a sedative commonly used in mechanical ventilation.
  • Its neuroprotective potential, particularly against oxidative stress, remains underexplored.
  • Motor neuron diseases are characterized by the degeneration of motor neurons.

Purpose of the Study:

  • To investigate the protective effects of Midazolam on motor neuron-like cells (NSC34) under oxidative stress.
  • To elucidate the role of the JNK-ERK signaling pathway in Midazolam's neuroprotective mechanism.
  • To assess Midazolam's potential as a therapeutic agent for motor neuron diseases.

Main Methods:

  • Utilized the NSC34 cell line, a hybrid motor neuron-like cell model.
  • Induced oxidative stress using oligomycin A and rotenone (O/R) or phenylarsine oxide.
  • Assessed apoptosis via TUNEL assay and cleaved Caspase-3 expression.
  • Analyzed the modulation of the JNK-ERK signaling pathway, including phosphorylation levels.

Main Results:

  • Midazolam demonstrated a significant protective effect against oxidative stress-induced cytotoxicity in NSC34 cells.
  • Apoptosis markers, including TUNEL+ cells and cleaved Caspase-3, were reduced by 22% and 45%, respectively.
  • Midazolam modulated the phosphorylation of JNK and ERK signaling pathways, influencing cell survival under oxidative stress.

Conclusions:

  • Midazolam exhibits previously unrecognized neuroprotective properties against oxidative stress in motor neuron-like cells.
  • The protective effects are mediated, in part, through the modulation of the JNK-ERK signaling pathway.
  • Midazolam shows promise as a potential therapeutic candidate for treating motor neuron diseases.

Related Concept Videos

Anxiolytic Drugs: Overview01:26

Anxiolytic Drugs: Overview

Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
1.3K
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
2.7K
Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
1.0K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
744
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.5K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
650